ClinicalTrials.gg
RecruitingNCT06376487Updated Apr 19, 2024

Pulmonary Aeration and Muscle Thickening Fraction: Association of Electrical Impedance Tomography and Ultrasound

An interventional study of Flow rate evaluation in Bronchiolitis, sponsored by Hospital Israelita Albert Einstein. Recruiting at 1 site in Brazil. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Hospital Israelita Albert Einstein · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
Up to 24 Months
Sex
All
01

Study summary

The goal of this prospective clinical study is to evaluate the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC) in Infants under 2 years of age with a diagnosis of bronchiolitis and indication for use of HFNC. The main question[s] it aims to answer are:

  • If the thickening fraction of the abdominal muscle and diaphragm will change at the different flow rates evaluated
  • If the end-expiration lung impedance (EELZ) will change at the different flow rates evaluated

The belt will be installed around the chest before the start of the change in flow rates and monitoring with Electrical Impedance Tomography (EIT) will be initiated. Patients will be positioned in dorsal decubitus elevated 10 to 20 degrees and monitoring will be performed continuously during all flow rate variations and also during the ultrasound performance.

Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

The randomization of the order of application of the phases will be carried out in blocks, so that the homogeneity of the sequences is maintained even if the collection is interrupted before reaching the total number of individuals. The blocks will be of size two and four and the test and production lists will be generated with the help of the R packages.

Read the detailed description

OBJECTIVES Main Objective To evaluate, in infants with respiratory failure secondary to bronchiolitis, the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC).

Secondary Objectives

  • To evaluate whether there is a correlation between thickening fraction and respiratory distress score.
  • To find values from the EIT data and the thickening fraction that can correlate with possible failure criteria for HFNC therapy.

    1. METHODS 5.1 Study Type and Location A prospective clinical study will be conducted in the Pediatric ICU of Hospital Israelite Albert Einstein from January 2024 to December 2025 5.2 Ethical Aspects This study will be submitted to the Ethics and Research Committee of the Hospital Israelite Albert Einstein. The risk of participating in this research is considered minimal, limited to the accidental loss of confidentiality of the data collected or to skin erythema at the site of application of the belt. Only after signing the informed consent form will the patient be prepared for the beginning of monitoring (Appendix 1) Protocol The tape will be installed around the chest before the start of the change in flow rates and monitoring with EIT will be initiated. Patients will be positioned in dorsal decubitus elevated 10 to 20 degrees and monitoring will be performed continuously during all flow rate variations and also during the ultrasound performance.

Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

5.5 Randomization: Randomization process The sequence of the flow values will be done using a tool software R 5.6 Clinical and demographic variables Demographic variables such as age, sex, Pediatric Index of Mortality Score (PIM2) (23) and viral screening will be collected when requested during routine hospitalization.

Of the clinical variables, respiratory rate (RR) will be assessed by counting the inspiratory cycles produced by EIT plethysmography in one minute. Heart rate (HR) and peripheral oxygen saturation (SpO2) will be obtained directly from the Infinity Delta multiparameter monitor (Dräger, Lubeck, Germany). Inspired oxygen fraction (FiO2). The Respiratory and Oxygenation Index (ROX index) will also be calculated, which is calculated by the ratio of SpO2/FiO2 by RR.

To evaluate respiratory distress, the investigators will use the respiratory distress score.

Electrical Impedance Tomography The recording of the electrical impedance variation over time is called plethysmogram and this provides information on the ventilation variation which is called Delta Z (∆Z) and has an excellent correlation with the volume variation assessed by computed tomography (25) and the minimum impedance (ZMIN) or ∆EELZ (end-expiration lung impedance) which is the baseline of the plethysmogram and corresponds to the FRC (26,27).

The unit of measurement commonly used to quantify changes in impedance amplitude is arbitrary unit (AU).The average of at least 5 sequential respiratory cycles for each patient, in each flow range, will be considered for evaluation, considering the moment of greatest stability within the final minute of the flow rate to be evaluated. Calculations to obtain delta Z were performed by subtracting the final moment of inspiration from the final moment of expiration. The changes in EELZ (∆EELZ) will be compared to the average EELZ at a flow rate of 0.5 L-kg-1-min-1 (reference flow rate). Therefore, by definition, the average ∆EELZ at the 0.5 L-kg-1-min-1 flow rate will be equal to zero. To obtain clinically meaningful values instead of AU values, the ∆EELZ will be normalized by the corresponding Delta Z at the reference flow rate (28). With this transformation, ∆EELZ can be interpreted as changes in lung aeration measured in multiples of Delta Z (tidal volumes). For example, if an infant has a mean Delta Z of 15 AU at flow rate of 0.5 L-kg-1-min-1, a ∆EELZ of 30 AU at flow rate of 2.0 L-kg-1-min-1 will be shown as 2 (an increase in lung volume twice the Delta Z at the reference flow rate).

Evaluation by ultrasound Serial measurements of thickness and thickening fraction of the diaphragm and abdominal muscle (rectus and oblique) will be collected through ultrasound images by previously trained staff. The images will be taken in the SonoSite M-Turbo® device, using an L25x (13-6 MHz) linear transducer. Heated water-based gel will be used for image acquisition.

For the diaphragm thickness measurements, the investigators used right hemidiaphragm with the linear transducer located between the anterior and middle axillary lines around the ninth intercostal space, in the diaphragmatic apposition zone (29,30). For the rectus abdominis thickness measurements the investigators used the linear transducer positioned 2 cm to the right and 2 cm above the umbilical scar. The external oblique, internal oblique and transverse muscles of the abdomen can be identified as three parallel layers, usually best visualized on the anterior axillary line, midway between the lower edge of the rib cage and the iliac crest (15,16) The window will be obtained in B-moded, and the measurement performed in M-mode. For the measurement of the thickening fraction, the investigators will use the formula ((Eins - Eex) /Ex) x 100), where Eins = thickness obtained at the end of inspiration and Eex = thickness obtained at the end of expiration.

02

Conditions studied

  • Bronchiolitis

Browse trials for

Keywords

  • Pulmonary;
  • Ventilation;
03

In context

Bronchiolitis

289 studies on the registry are indexed under Bronchiolitis; 51 are open to participants now.

This study's planned enrollment of 82 is below the median of 100 across 195 interventional studies indexed under Bronchiolitis.

Browse Bronchiolitis studies →

Lead sponsor

Hospital Israelita Albert Einstein is the lead sponsor of 147 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bronchiolitis
  • Use of HFNC

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with chronic diseases
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    flow rate sequence

    Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

    Device: Flow rate evaluation

Interventions

  • DeviceFlow rate evaluation

    Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.

06

What researchers measure

Primary outcomes

  1. diaphragm thickening fraction

    to evaluate the diaphragm thickening fraction through ultrasound in infants with bronchiolitis using HFNC at 4 different flow rates, whether the diaphragm thickening fraction changes when the flow rate is changed

    Time frame: during procedure

  2. abdominal muscle thickening fraction

    to evaluate the abdominal muscle thickening fraction through ultrasound in infants with bronchiolitis using HFNC at 4 different flow rates, whether the abdominal muscle thickening fraction changes when the flow rate is changed

    Time frame: during procedure

  3. EELZ (end-expiration lung impedance)

    to evaluate the EELZ through electrical impedance tomography in infants with bronchiolitis using HFNC at 4 different flow rates, whether there is a change in the EELZ when the flow rate is changed

    Time frame: during procedure

07

Study locations

1 of 1 sites recruiting
  • Hospital Israelita Albert Eisntein
    São Paulo, 05653000, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This study will be in partnership with Childrens Hospital Los Angeles. The anonymized database will be shared containing all variables described in the methodology

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The data will be shared after the inclusion of patients until the analysis of the results is completed

Access criteria: All data will be compiled and managed in the electronic data capture system "Research Electronic Data Capture" (REDCap) hosted on the servers of Hospital Israelite Albert Einstein (HIAE) (33). All data, when made available to the project team, will be made available in a de-identified form in order to protect the participant's identity and guarantee the integrity of the data.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06376487
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo, Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
May 1, 2024 (estimated)
Primary completion
Jul 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Apr 19, 2024

Study contacts

Milena S Nascimento
Contact
milena.nascimento@einstein.br
55 11 984520061
Milena S Nascimento
principal investigator · Hospital Israelita Albert Einstein
Celso M Rebello
study chair · Hospital Israelita Albert Einstein

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion